Actinogen Medical Ltd
ACW
Company Profile
Business description
Actinogen Medical Ltd is a biotechnology company. The company develops a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated cortisol in the brain. It is focused on the clinical development of Xanamem, an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Geographically, the company's income is derived in Australia.
Contact
109 Pitt Street
Level 9, Suite 901
SydneyNSW2000
AUST: +61 289647401
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
Stocks News & Analysis
stocks
SK Hynix Earnings: We raise fair value estimate on strong AI memory demand
Shares jumped 9% after earnings, as stronger AI memory prices boosted the chipmaker’s outlook.
stocks
Meta shares are down 12% since earnings. Is the stock a buy?
Concerns about equity sales to finance AI investments have pressured shares.
stocks
SpaceX earnings: We raise our fair value estimate on scaling data centres, but is the stock a buy?
AI data center revenue is growing fast, but questions about durability remain.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,971.40 | 2.60 | 0.03% |
| CAC 40 | 7,886.96 | 0.18 | -0.00% |
| DAX 40 | 25,704.02 | 113.25 | 0.44% |
| Dow JONES (US) | 52,475.10 | 97.53 | 0.19% |
| FTSE 100 | 10,694.50 | 7.96 | 0.07% |
| HKSE | 23,094.83 | 53.51 | 0.23% |
| NASDAQ | 26,549.85 | 72.04 | 0.27% |
| Nikkei 225 | 63,954.19 | 685.82 | 1.08% |
| NZX 50 Index | 13,689.77 | 1.56 | -0.01% |
| S&P 500 | 7,743.98 | 21.38 | 0.28% |
| S&P/ASX 200 | 8,847.30 | 2.80 | -0.03% |
| SSE Composite Index | 3,681.47 | 33.17 | 0.91% |